Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK4172239D in sickle cell disease
NCT05660265Phase 1Terminated
- Sponsor
- GSK
- Start
- Aug 2023
- Primary completion
- Sep 2025
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK4172239 in sickle cell disease (SCD) (6 cohorts), sponsored by GSK. Primary endpoints: Area Under Curve Zero to Time Infinity for GSK4106401 at 3 days, Maximum Observed Plasma Concentration for GSK4106401 at 3 days and 4 more. Started Aug 2023; status: terminated.
02
Drugs
GSK4172239
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05660265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05660265.